Prime Medicine, Inc. (PRME) stock
PRMENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.84−0.35 (-8.35%)
Close on Nov 17, 2026Market cap $696.49MP/E –Yield –
Prime Medicine cash
Cash and short-term investments held at the end of each period.
Prime Medicine's cash was $95.10M at Jun 30, 2026. For fiscal 2025 it was $177.70M, down 6.7% from the year before. The highest annual figure on record is $293.90M in fiscal 2022.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $177.70M | -6.7% |
| FY2024 | Dec 31, 2024 | $190.40M | +56.5% |
| FY2023 | Dec 31, 2023 | $121.70M | -58.6% |
| FY2022 | Dec 31, 2022 | $293.90M | +10.2% |
| FY2021 | Dec 31, 2021 | $266.78M | +621.5% |
| FY2020 | Dec 31, 2020 | $36.98M | +327.6% |
| FY2019 | Dec 31, 2019 | $8.65M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $95.10M | -6.6% |
| Q1 FY2026 | Mar 31, 2026 | $135.50M | -6.1% |
| Q4 FY2025 | Dec 31, 2025 | $177.70M | -6.7% |
| Q3 FY2025 | Sep 30, 2025 | $213.30M | +21.5% |
| Q2 FY2025 | Jun 30, 2025 | $101.80M | -37.5% |
| Q1 FY2025 | Mar 31, 2025 | $144.30M | -31.5% |
| Q4 FY2024 | Dec 31, 2024 | $190.40M | +56.5% |
| Q3 FY2024 | Sep 30, 2024 | $175.50M | +6.2% |
| Q2 FY2024 | Jun 30, 2024 | $162.90M | -21.5% |
| Q1 FY2024 | Mar 31, 2024 | $210.70M | -15.6% |
| Q4 FY2023 | Dec 31, 2023 | $121.70M | -58.6% |
| Q3 FY2023 | Sep 30, 2023 | $165.30M | +12.7% |
| Q2 FY2023 | Jun 30, 2023 | $207.60M | +125.1% |
| Q1 FY2023 | Mar 31, 2023 | $249.50M | +51.9% |
| Q4 FY2022 | Dec 31, 2022 | $293.90M | +10.2% |
| Q3 FY2022 | Sep 30, 2022 | $146.70M | -26.9% |
| Q2 FY2022 | Jun 30, 2022 | $92.24M | +149.5% |
| Q1 FY2022 | Mar 31, 2022 | $164.25M | +1799.5% |
| Q4 FY2021 | Dec 31, 2021 | $266.78M | – |
| Q3 FY2021 | Sep 30, 2021 | $200.66M | – |
| Q4 FY2020 | Dec 31, 2020 | $36.98M | – |
| Q4 FY2019 | Dec 31, 2019 | $8.65M | – |
See a number that looks wrong?